Check your mailbox If your details match an order, you'll receive an email with a link to view and manage it.
Doxil synergizes with Cancer immunotherapies to enhance antitumor responses in syngeneic mouse models
In 2025, only about 19% of companies with 200 or more workers and 43% of firms with 5,000 or more employees covered GLP-1s for weight loss in their largest health plan
About 2 weeks until it reached my door which I think is quite a lot. [14] However, reviews from researchers should hold no weight in what vendor a researcher decides to use for their study
This has several important implications for manufacturers: Early launch benchmarks may understate success if they focus primarily on switching behavior rather than new-to-therapy initiation The addressable market for oral GLP-1s may be larger than previously modeled , particularly if similar barriers exist across obesity and cardiometabolic indications Pipeline assets following oral semaglutide may enter a more receptive market , where the viability of oral administration has already been established What Great Looks Like: Speed and Clinical Depth at Launch Imagine if, within weeks of launch, pharma leaders could understand the earliest signals of launch performanceincluding prescription activity, patient flow, site of care, and early access dynamicsby assessing near-real-time, large-scale claims and EMR data
Chromatographic fingerprint analysis, antioxidant properties, and inhibition of cholinergic enzymes (acetylcholinesterase and butyrylcholinesterase) of phenolic extracts from Irvingia gabonensis (aubry-Lecomte ex ORorke) baill bark
